| # | Title | Journal | Year | Citations |
|---|
| 1 | Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study | Lancet Respiratory Medicine,the | 2020 | 7,975 |
| 2 | Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Lancet Respiratory Medicine,the | 2020 | 6,934 |
| 3 | Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | Lancet Respiratory Medicine,the | 2020 | 2,241 |
| 4 | Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis | Lancet Respiratory Medicine,the | 2019 | 1,866 |
| 5 | Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study | Lancet Respiratory Medicine,the | 2015 | 1,755 |
| 6 | Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 | Lancet Respiratory Medicine,the | 2017 | 1,672 |
| 7 | Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations | Lancet Respiratory Medicine,the | 2020 | 1,177 |
| 8 | Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans | Lancet Respiratory Medicine,the | 2020 | 1,080 |
| 9 | Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | Lancet Respiratory Medicine,the | 2020 | 1,049 |
| 10 | COVID-19 cytokine storm: the interplay between inflammation and coagulation | Lancet Respiratory Medicine,the | 2020 | 1,011 |
| 11 | Rational use of face masks in the COVID-19 pandemic | Lancet Respiratory Medicine,the | 2020 | 1,000 |
| 12 | Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials | Lancet Respiratory Medicine,the | 2014 | 992 |
| 13 | Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Lancet Respiratory Medicine,the | 2015 | 937 |
| 14 | Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit | Lancet Respiratory Medicine,the | 2014 | 864 |
| 15 | Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy | Lancet Respiratory Medicine,the | 2020 | 802 |
| 16 | Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial | Lancet Respiratory Medicine,the | 2020 | 789 |
| 17 | Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial | Lancet Respiratory Medicine,the | 2016 | 754 |
| 18 | Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper | Lancet Respiratory Medicine,the | 2018 | 739 |
| 19 | E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis | Lancet Respiratory Medicine,the | 2016 | 713 |
| 20 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial | Lancet Respiratory Medicine,the | 2019 | 704 |
| 21 | Respiratory risks from household air pollution in low and middle income countries | Lancet Respiratory Medicine,the | 2014 | 670 |
| 22 | Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes | Lancet Respiratory Medicine,the | 2020 | 661 |
| 23 | Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study | Lancet Respiratory Medicine,the | 2018 | 638 |
| 24 | The global burden of paediatric and neonatal sepsis: a systematic review | Lancet Respiratory Medicine,the | 2018 | 630 |
| 25 | Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study | Lancet Respiratory Medicine,the | 2020 | 628 |
| 26 | Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial | Lancet Respiratory Medicine,the | 2015 | 614 |
| 27 | Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial | Lancet Respiratory Medicine,the | 2014 | 594 |
| 28 | Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials | Lancet Respiratory Medicine,the | 2015 | 583 |
| 29 | The future of cystic fibrosis care: a global perspective | Lancet Respiratory Medicine,the | 2020 | 573 |
| 30 | Pulmonary sarcoidosis | Lancet Respiratory Medicine,the | 2018 | 544 |
| 31 | Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study | Lancet Respiratory Medicine,the | 2016 | 536 |
| 32 | Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data | Lancet Respiratory Medicine,the | 2014 | 527 |
| 33 | A global view of pulmonary hypertension | Lancet Respiratory Medicine,the | 2016 | 523 |
| 34 | Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study | Lancet Respiratory Medicine,the | 2020 | 516 |
| 35 | Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11 | Lancet Respiratory Medicine,the | 2014 | 513 |
| 36 | Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe | Lancet Respiratory Medicine,the | 2017 | 502 |
| 37 | Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial | Lancet Respiratory Medicine,the | 2021 | 501 |
| 38 | COVID-19 and the impact of social determinants of health | Lancet Respiratory Medicine,the | 2020 | 498 |
| 39 | Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study | Lancet Respiratory Medicine,the | 2014 | 487 |
| 40 | Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study | Lancet Respiratory Medicine,the | 2013 | 486 |
| 41 | Protecting health-care workers from subclinical coronavirus infection | Lancet Respiratory Medicine,the | 2020 | 483 |
| 42 | Management of acute kidney injury in patients with COVID-19 | Lancet Respiratory Medicine,the | 2020 | 467 |
| 43 | Ambient air pollution and low birthweight: a European cohort study (ESCAPE) | Lancet Respiratory Medicine,the | 2013 | 464 |
| 44 | An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial | Lancet Respiratory Medicine,the | 2014 | 464 |
| 45 | Sex difference and smoking predisposition in patients with COVID-19 | Lancet Respiratory Medicine,the | 2020 | 463 |
| 46 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis | Lancet Respiratory Medicine,the | 2017 | 459 |
| 47 | Minimum clinically important difference for the COPD Assessment Test: a prospective analysis | Lancet Respiratory Medicine,the | 2014 | 458 |
| 48 | Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study | Lancet Respiratory Medicine,the | 2013 | 456 |
| 49 | Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial | Lancet Respiratory Medicine,the | 2018 | 455 |
| 50 | 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study | Lancet Respiratory Medicine,the | 2021 | 451 |
